132 related articles for article (PubMed ID: 34688409)
1. A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy.
Del Rosso M; Fibbi G; Laurenzana A; Margheri F; Chillà A
J Invest Dermatol; 2021 Nov; 141(11):2566-2568. PubMed ID: 34688409
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
Tseng YJ; Lee CH; Chen WY; Yang JL; Tzeng HT
J Invest Dermatol; 2021 Nov; 141(11):2690-2698.e6. PubMed ID: 34000287
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma.
Emmons MF; Smalley KSM
J Invest Dermatol; 2022 Jan; 142(1):18-20. PubMed ID: 34565560
[TBL] [Abstract][Full Text] [Related]
5. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
6. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor-1 regulates infiltration of macrophages into melanoma via phosphorylation of FAK-Tyr⁹²⁵.
Thapa B; Koo BH; Kim YH; Kwon HJ; Kim DS
Biochem Biophys Res Commun; 2014 Aug; 450(4):1696-701. PubMed ID: 25063025
[TBL] [Abstract][Full Text] [Related]
8. Firing up the cold tumors by targeting Vps34.
Janji B; Hasmim M; Parpal S; Berchem G; Noman MZ
Oncoimmunology; 2020 Aug; 9(1):1809936. PubMed ID: 32939326
[TBL] [Abstract][Full Text] [Related]
9. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
10. The High Affinity Binding Site on Plasminogen Activator Inhibitor-1 (PAI-1) for the Low Density Lipoprotein Receptor-related Protein (LRP1) Is Composed of Four Basic Residues.
Gettins PG; Dolmer K
J Biol Chem; 2016 Jan; 291(2):800-12. PubMed ID: 26555266
[TBL] [Abstract][Full Text] [Related]
11. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
13. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
Eitzman DT; Krauss JC; Shen T; Cui J; Ginsburg
Blood; 1996 Jun; 87(11):4718-22. PubMed ID: 8639841
[TBL] [Abstract][Full Text] [Related]
14. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
15. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
[TBL] [Abstract][Full Text] [Related]
16. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
18. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.
Ganbaatar O; Konnai S; Okagawa T; Nojima Y; Maekawa N; Minato E; Kobayashi A; Ando R; Sasaki N; Miyakoshi D; Ichii O; Kato Y; Suzuki Y; Murata S; Ohashi K
PLoS One; 2020; 15(11):e0234218. PubMed ID: 33216754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]